Table 1.

Everolimus dose modifications for non-hematologic adverse events (excluding metabolic events)

Severity	Everolimus dose adjustmenta	Management recommendations
Grade 1	No dose adjustment required	Initiate appropriate medical therapy and monitor
Grade 2	If toxicity is tolerable, no dose adjustment required If toxicity becomes intolerable, temporary dose interruption until recovery to grade ≤1. Reinitiate EVE at same doseb If toxicity recurs at grade 2, interrupt EVE until recovery to grade ≤1. Reinitiate EVE at a lower dose	Initiate appropriate medical therapy and monitor
Grade 3	Temporary dose interruption until recovery to grade ≤1 Consider reinitiating EVE at a lower dose If toxicity recurs at grade 3, consider discontinuation	Initiate appropriate medical therapy and monitor
Grade 4	Discontinue EVE	Treat with appropriate medical therapy

AE, adverse event; EVE, everolimus.

^aIf dose reduction is required, the suggested dose is ∼50% lower than the dose previously administered.

^bFor non-infectious pneumonitis, everolimus should be reinitiated at a lower dose level (everolimus package insert, 2012).